VALacyclovir In Delaying Antiretroviral Treatment Entry

CompletadoFase 3ClinicalTrials.gov

ID: NCT00860977Tipo: INTERVENTIONALInicio: 1 de mar de 2010Fin estimado: 1 de ago de 2015

Traducción no disponible, mostrando original

Resumen

This study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of twice daily oral valacyclovir 500mg versus placebo with the goal of delaying the need for initiating HAART among HIV infected individuals who neither use nor require HAART, and who have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study initiation.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

adult (aged 18 years or older or as per Local/Provincial Guidelines)
documented HIV-1 infection (determined by EIA and Western blot, sites' standard assays are acceptable if approved in advance by the PIs for the study, Dr. Darrell Tan and/or Dr. Sharon Walmsley)
no use of chronic anti-HSV therapy for the past 6 months, and not anticipated to require chronic anti-HSV therapy during the study
antiretroviral naïve (no more than 14 days of total prior ARV exposure)
CD4 count within the 400-900 cells/mm3 range (inclusive) on two consecutive occasions, with at least one measurement within 30 days of initiating trial (baseline visit)
does not meet recommendations for initiating ARV therapy according to current guidelines

Criterios de exclusión

pregnancy or actively planning to become pregnant
receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications (e.g. interferon, azathioprine, methotrexate, TNF-alpha antagonists, etc.)
Estimated creatinine clearance \<30 mL/min
Other medical condition likely to cause death within 24 months
Enrolled in a therapeutic HIV vaccine or immunotherapy trial
Enrolled in another trial investigating the impact of another intervention on HIV disease progression
HIV elite controller (EC), phenotypically defined here as documented duration of HIV infection of ≥5 years, a persistent CD4 cell count ≥500 cells/mm3, and a persistent plasma HIV viral load of \<1000 copies/mL in the absence of antiretroviral therapy

Intervenciones

drug

valacyclovir

oral valacyclovir 500mg twice daily

drug

Placebo

Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily

Ubicaciones

Fundación Huesped

Buenos Aires, Argentina

Patrocinadores

PrincipalUniversity Health Network, Toronto

ColaboradorCIHR Canadian HIV Trials Network

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

VALacyclovir In Delaying Antiretroviral Treatment Entry | EligiMed